Workshop
Drug-Drug Interactions: Update on Risk Assessment, Clinical Evaluation, and Regulatory Requirements
Speakers:
Simon Wong, Jing Wang, Jialin Mao, Kari Morrissey (Genentech); Jingjing Yu (UW); Xinning Yang (FDA); Ilaria Badagnani (Theravance Biopharma); Yurong Lai (Gilead)
Organizers:
Simon Wong (Genentech), Snow Ge (Nektar)
Date:
2018-10-16
Time:
8:45-17:00 Pacific Time
Registration fee:
(USD): Regular: $195; Academic: $125; For unemployed or students: $30; For vendor-show rep: $35; For major-sponsor rep (incl lunch): $0
Location:
SF Bay Area: Foster City Crowne Plaza
Major Sponsor:
Vendor show vendors registered to date:
(22)Absorption Systems; Altasciences; BioDuro; BioreclamationIVT; Celerion; Concept Life Sciences; Corning; Covance; Cyprotex; Cytovier; Intertek; KCAS Bio; Lonza; MicroConstants; Novabiosis, Inc; Quintara Discovery (QDI); Quotient Sciences; Sekisui XenoTech, LLC; Seventh Wave; Simulations Plus, Inc.; SOLVO Biotechnology; WORLDWIDE CLINICAL TRIALS
Registration: http://www.PBSS.org
Registration deadline:2018-10-14
(it will close sooner if the seating cap is reached)
About the Topic
The potential for clinical drug-drug interactions (DDIs) continues to be of key liability for the development of new medicines. This comprehensive workshop will review techniques and strategy to assess the potential for DDI's from early discovery to clinical development. In addition, clinical case studies will be explored highlighting interactions with regulatory authorities and accompanying strategies to understand and mitigate risk and expedite compound advancement.
Specific topics to be covered:
- Assessment of enzyme-based DDI's (induction/inhibition) and reaction phenotyping
- Large molecule therapeutic protein interactions with small molecules
- Recent strategies to utilize physiologically-based modeling for risk assessment
- Update on transporter-mediated DDI's and clinical assessment
- Design and interpretation of clinical DDI studies
- Clinically relevant biomarkers for the assessment of transporter-mediated DDI's
- Update and commentary on recent (2017) FDA draft guidance for DDI's
Workshop Agenda
8:45-8:50 PBSS Welcome - Simon Wong (Genentech)
8:50-9:25 1. Introduction and DDI Basics on Inhibition, Induction and Reaction Phenotyping - Simon Wong (Genentech)
9:25–10:00 2. Assessment of Therapeutic Protein Drug-Drug Interactions with Small Molecules - Jing Wang (Genentech)
10:00-10:10 Major Sponsor Presentation - TBD
10:10-10:35 Break & Vendor Show
10:35-11:20 3. Physiologically-Based Modelling and DDI Risk Assessment - Jialin Mao (Genentech)
11:20–12:00 4. Design and Interpretation of Clinical DDI Studies - Kari Morrissey (Genentech)
12:00-1:00 Lunch
1:00–1:45 5. What Can Be Learned from Recent NDAs? Key Findings on Drug Interactions for Drugs Approved by the FDA - Jingjing Yu (University of Washington)
1:45–2:30 6. Update of DDI Draft Guidance - Xinning Yang (FDA)
2:30-2:40 Major Sponsor Presentation - TBD
2:40-3:00 Break & Vendor Show
3:00-3:45 7. Transporter-mediated DDIs – What’s new in 2017 FDA draft guidance and industry application and risk assessment - Ilaria Badagnani (Theravance Biopharma)
4:00-4:45 8. Clinical Biomarkers for Transporter Mediated DDI - Yurong Lai (Gilead)
4:45-5:15 Panel Discussion - All
2024-04-26, [In-Person] Oncology Clinical Dose Optimization in Light of FDA Project Optimus
|
2024-05-06, [In-Person] Human Mass Balance and Metabolite Profiling Studies: Strategies, Technical Approaches, Regulatory Guidance, Applications and Case Studies
|
2024-05-13, [Free Online] Highlights of 2023 FDA Drug Approvals
|
2024-05-21, [In-Person] Nonclinical Safety Studies for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
|
2024-05-30, [Free Online Workshop] Career Transition for Research Scientists: Career Overview, Project Management and Regulatory Affairs (jointly with BioPharmaPM and RAPS-SF)
|
2024-06-13, [In-Person] CMC Strategies and Activities for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
|
2024-06-20, Alzheimer's Disease: untangling what we thought we knew and future Precision Medicine Diagnostics and Therapeutics
|
2024-07-24, [Free Online] The Science and Stories of Promising Biotech Startups: Symposium No.6
|
2024-09-10, [In-Person] Rethinking Translational PK/PD and Human Dose Projections for Novel Therapeutic Modalities: Covalent Inhibitors, PROTACs, Molecular Glues, ADCs, Ocular and Neuro delivery, Vaccines, Bispecifics, Cell and Gene Therapies
|
2024-09-20, [In-Person] Non-clinical safety assessments of biologics and novel modalities for IND/NDA Filing: Nuts, Bolts and Best Practices
|
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
|